FLNA
Filana Therapeutics Inc. Common Stock (FLNA)
Healthcare • NASDAQ • $0.96+1.96%
- Symbol
- FLNA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.96
- Daily Change
- +1.96%
- Market Cap
- $44.12M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $4.98
- 52W Low
- $0.86
- Analyst Target
- $6.50
- Dividend Yield
- N/A
- Beta
- -0.69
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Company websiteResearch FLNA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.